TrialsgrambetaRCTs are beautiful

APPLAUSE-IgAN

2025

Iptacopan in Primary IgA Nephropathy

In 250 patients with IgA nephropathy and persistent proteinuria, the factor-B inhibitor iptacopan reduced proteinuria compared with placebo.

Result

Primary endpoint: Reduction in 24-hour UPCR (month-9 interim); annualised eGFR slope

38.3% greater UPCR reduction versus placebo (p<0.0001); 2-year data met the eGFR-slope endpoint.

Original publication
Subtopic
IgA nephropathy
Design
Phase 3 double-blind RCT
Relevance
Supporting: context rather than must-know.
Source
Perkovic V, et al. N Engl J Med. 2025;392(6):531-543.doi 10.1056/NEJMoa2410316

Discussion & critique

First complement factor-B inhibitor for IgA nephropathy; accelerated FDA approval of Fabhalta in 2024.

Discussed in podcasts